Orchard Park, NY– October 7, 2020– Aging-US recently published “From Causes of Aging to Death from COVID-19” by Blagosklonny et al. which reported that COVID-19 is not deadly early in life, but mortality increases exponentially with age. This makes age the strongest predictor of mortality for COVID-19, surpassing other risk factors, like obesity and smoking.
Since the beginning of the pandemic, age was considered a serious factor in regard to the death-rate of COVID-19 with numbers skyrocketing for patients over the age of after the age of 65, 75 and 85. Yet, age is often considered an additional risk factor instead of the sole leading risk factor of COVID-19.
Age alone is not a risk, but the diseases and slowing body processes that come with age. When additional health concerns are paired with the COVID-19 virus, the body can’t react adequately and the immune response is exacerbated. Treating age as the leading risk factor clarifies the top treatment options through an overarching cause and not focusing on manifestations that come secondary.
The risk factor of age is typically compounded with other risk factors that are manifestations of biological age. This means that aging and diseases are often two sides of the same coin. Age-related diseases mentioned by the article include: hypertension, diabetes, obesity, ischemic heart disease, chronic obstructive pulmonary disease, and other similar diseases that have also been linked to the severity of COVID-19.
The The Aging-US Review reported as soon as the COVID-19 epidemic started, it was clear age was a major factor in the severity of COVID-19. Because this vulnerability is an aging-dependent condition, the use of rapamycin was immediately suggested by independent researchers.
The review states, “Figuratively, rapamycin rejuvenates immunity”, mTOR inhibitors can improve immunity to viral infections, improve immunization and vaccination to some viruses such as the flu.
The Blagosklonny Research Team goes on to highlight that an anti-aging intervention, such as rapamycin, may slow aging and age-related diseases, potentially decreasing COVID-19 vulnerability. By decreasing biological age and preventing age-related diseases, long-term rapamycin therapy may, in theory, decrease the COVID-19 mortality rate in the elderly.
By decreasing biological age and preventing age-related diseases, long-term rapamycin therapy may, in theory, decrease the COVID-19 mortality rate in the elderly. Rapamycin is also an anti-inflammatory agent, which is the main cause of COVID-19 deaths.
Launched in 2009, Aging-US publishes papers of general interest and biological significance in all fields of aging research as well as topics beyond traditional gerontology. This includes, but is not limited to, cellular and molecular biology, human age-related diseases, pathology in model organisms, cancer, signal transduction pathways (e.g., p53, sirtuins, and PI-3K/AKT/mTOR among others), and approaches to modulating these signaling pathways.